GlassScriptPhysician profile
Stefan Charles Grant
NPI 1407979032
$9,480.03
in general payments reported to CMS, 2019-2025
24 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $64.99 · 2022: $212 · 2023: $8,646 · 2024: $217 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,646 · Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,646.00 |
| Food and Beverage | $557.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $8,646.00 | 2023 | Foundationone Cdx |
| Novocure Gmbh | $200.00 | 2022 | |
| Daiichi Sankyo INC. | $76.01 | 2024 | Enhertu, Vanflyta |
| Genentech USA, INC. | $64.99 | 2020 | |
| Merck Sharp & Dohme LLC | $59.11 | 2024-2025 | Keytruda, Welireg |
| Aveo Pharmaceuticals, INC. | $51.88 | 2025 | |
| Novartis Pharmaceuticals Corporation | $51.46 | 2024-2025 | |
| Array Biopharma INC | $49.25 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Jazz Pharmaceuticals INC. | $38.44 | 2025 | |
| Servier Pharmaceuticals LLC | $36.51 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $35.06 | 2025 | Libtayo |
| Pharmaessentia USA Corporation | $31.31 | 2025 | Besremi |
| Phathom Pharmaceuticals, INC. | $27.92 | 2024 | Voquezna |
| Eisai INC. | $24.77 | 2024 | |
| Adaptive Biotechnologies Corporation | $22.98 | 2024 | Clonoseq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $21.27 | 2025 | Enhertu |
| Janssen Biotech, INC. | $17.26 | 2025 | Talvey |
| Dendreon Pharmaceuticals LLC | $13.81 | 2025 | Provenge |
| Pfizer INC. | $12.00 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.